Utkan Karasu Ayça, Kılıç Ayza, Karaoğlan Belgin
Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Gazi University, 06500 Ankara, Turkey.
J Clin Med. 2024 Dec 7;13(23):7462. doi: 10.3390/jcm13237462.
This study assessed Transcutaneous Pulse Radiofrequency Therapy's (TCPRF) effectiveness in reducing shoulder pain and improving shoulder function. A double-blind randomized controlled trial involved 50 SAIS patients with chronic shoulder pain. Participants were randomized into two groups: the study group (n = 27) received TCPRF, while the control (n = 23) received sham treatment. The primary outcome was shoulder pain, secondary outcomes, including shoulder function, quality of life, and range of motion, were assessed at baseline, and at 1, 4, and 12 weeks using the Visual Analog Scale (VAS), Shoulder Pain and Disability Index (SPADI), and the SF-36 questionnaire. Supraspinatus tendon thickness (SSPT) and acromiohumeral distance (AHD) were measured by ultrasound. Both groups showed reductions in activity and resting pain over 12 weeks. In the control, activity pain dropped from a median (IQR) of 8 (7-8) to 6 (3-7), and in TCPRF from 8 (7-10) to 3.5 (2-6.3), with no significant difference at 12 weeks ( = 0.192). Resting pain decreased from 3 (1-6) to 1 (1-3) in the control, and from 3 (2-4) to 0 (0-2) in TCPRF, showing a lower resting pain at 12 weeks ( = 0.041). SPADI-Total scores decreased from 87 (54-105) to 50 (29-82) in the control and from 84 (69-107) to 21 (9-66.3) in TCPRF, favoring TCPRF at 12 weeks ( = 0.017). SPADI-Disability scores reduced from 49 (30-63) to 30 (15-30) in control and from 47 (35-62) to 11 (5.8-38.8) in TCPRF, also favoring TCPRF ( = 0.008). Both groups showed similar improvements in other outcomes. TCPRF reduced resting pain and shoulder disability in SAIS over 12 weeks, though other outcomes showed similar improvement in both groups. Further studies are needed to determine long-term effects.
本研究评估了经皮脉冲射频治疗（TCPRF）在减轻肩部疼痛和改善肩部功能方面的有效性。一项双盲随机对照试验纳入了50例患有慢性肩部疼痛的肩峰下撞击综合征（SAIS）患者。参与者被随机分为两组：研究组（n = 27）接受TCPRF治疗，而对照组（n = 23）接受假治疗。主要结局指标为肩部疼痛，次要结局指标包括肩部功能、生活质量和活动范围，在基线以及第1、4和12周时使用视觉模拟量表（VAS）、肩部疼痛和功能障碍指数（SPADI）以及SF-36问卷进行评估。通过超声测量冈上肌腱厚度（SSPT）和肩峰下间隙（AHD）。两组在12周内的活动期和静息期疼痛均有所减轻。对照组的活动期疼痛从中位数（四分位间距）8（7 - 8）降至6（3 - 7），TCPRF组从8（7 - 10）降至3.5（2 - 6.3），在12周时无显著差异（P = 0.192）。对照组的静息期疼痛从3（1 - 6）降至1（1 - 3），TCPRF组从3（2 - 4）降至0（0 - 2），在12周时TCPRF组静息期疼痛更低（P = 0.041）。对照组的SPADI总分从87（54 - 105）降至50（29 - 82），TCPRF组从84（69 - 107）降至21（9 - 66.3），在12周时TCPRF组更具优势（P = 0.017）。对照组的SPADI功能障碍评分从49（30 - 63）降至30（15 - 30），TCPRF组从47（35 - 62）降至11（5.8 - 38.8），同样TCPRF组更具优势（P = 0.008）。两组在其他结局指标上显示出相似的改善。TCPRF在12周内减轻了SAIS患者的静息期疼痛和肩部功能障碍，尽管两组在其他结局指标上显示出相似的改善。需要进一步研究以确定其长期效果。
